HUTCHMED China Ltd Market Cap ($21.47 Million)
Market Cap & Net Worth: HUTCHMED China Ltd (HCM)
HUTCHMED China Ltd market cap. HUTCHMED China Ltd (LSE:HCM) has a market capitalization of $21.47 Million (GBX176.42 Billion) as of October 31, 2026. Listed on the LSE stock exchange, this UK-based company holds position #24738 globally and #245 in its home market, demonstrating a -9.38% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying HUTCHMED China Ltd's stock price GBX203.00 by its total outstanding shares 869070839 (869.07 Million).
HUTCHMED China Ltd Market Cap History (2015–2026)
HUTCHMED China Ltd market cap history from 2015 to 2026. Data shows change from $29.50 Million to $20.94 Million (-1.04% CAGR). Check HCM live share price for real-time trading data and today's change.
Index Memberships
HUTCHMED China Ltd is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
FTSE AIM All Share Index
FTAI
|
$993.18 Million | 2.16% | #6 of 722 |
Weight: HUTCHMED China Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
HUTCHMED China Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how HUTCHMED China Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see HCM operating cash flow for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
0.04x
HUTCHMED China Ltd's market cap is 0.04 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.05x
HUTCHMED China Ltd's market cap is 0.05 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $24.00 Million | $216.08 Million | $11.70 Million | 0.11x | 2.05x |
| 2017 | $59.21 Million | $241.20 Million | -$26.74 Million | 0.25x | N/A |
| 2018 | $37.01 Million | $214.11 Million | -$74.81 Million | 0.17x | N/A |
| 2019 | $40.18 Million | $204.89 Million | -$103.68 Million | 0.20x | N/A |
| 2020 | $48.64 Million | $227.98 Million | -$125.73 Million | 0.21x | N/A |
| 2021 | $56.04 Million | $356.13 Million | -$194.65 Million | 0.16x | N/A |
| 2022 | $27.92 Million | $426.41 Million | -$360.83 Million | 0.07x | N/A |
| 2023 | $29.92 Million | $838.00 Million | $100.78 Million | 0.04x | 0.30x |
| 2024 | $24.85 Million | $630.20 Million | $37.73 Million | 0.04x | 0.66x |
| 2025 | $21.99 Million | $548.65 Million | $457.02 Million | 0.04x | 0.05x |
Competitor Companies of HCM by Market Capitalization
Companies near HUTCHMED China Ltd in the global market cap rankings as of October 31, 2026. See HCM equity financing ratio to understand what proportion of total assets are financed by equity.
Key companies related to HUTCHMED China Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #511 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #535 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #593 globally with a market cap of $45.23 Billion USD ( CN¥309.13 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #619 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #511 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #535 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $46.62 |
| #593 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.23 Billion | CN¥48.46 |
| #619 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.30 |
Market Capitalization of HUTCHMED China Ltd (2015–2026)
Market capitalization of HUTCHMED China Ltd from 2015 to today. Between 2015 and today, HUTCHMED China Ltd's market cap moved from $29.50 Million to $ 20.94 Million, with a yearly change of -1.04%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | GBX20.94 Million | -4.81% |
| 2025 | GBX21.99 Million | -11.49% |
| 2024 | GBX24.85 Million | -16.96% |
| 2023 | GBX29.92 Million | +7.20% |
| 2022 | GBX27.92 Million | -50.19% |
| 2021 | GBX56.04 Million | +15.22% |
| 2020 | GBX48.64 Million | +21.05% |
| 2019 | GBX40.18 Million | +8.57% |
| 2018 | GBX37.01 Million | -37.50% |
| 2017 | GBX59.21 Million | +146.70% |
| 2016 | GBX24.00 Million | -18.64% |
| 2015 | GBX29.50 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 10th, 2026 the market cap of HUTCHMED China Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $21.47 Million USD |
| MoneyControl | $21.47 Million USD |
| MarketWatch | $21.47 Million USD |
| marketcap.company | $21.47 Million USD |
| Reuters | $21.47 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About HUTCHMED China Ltd
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast c… Read more